These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7505717)

  • 1. Drug formulary review process for sargramostim and filgrastim: focus on analysis of adverse drug reactions.
    Kellihan MJ
    Clin Ther; 1993; 15(5):927-37. PubMed ID: 7505717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction.
    Engler RJ; Weiss RB
    Ann Allergy Asthma Immunol; 1996 Jun; 76(6):531-4. PubMed ID: 8673688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effects of biologic response modifiers.
    Louie SG; Jung B
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S10-8. PubMed ID: 7689788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of filgrastim, sargramostim, and sequential sargramostim and filgrastim after myelosuppressive chemotherapy.
    Weaver CH; Buckner CD; Curtis LH; Bajwa K; Weinfurt KP; Wilson-Relyea BJ; Schulman KA
    Bone Marrow Transplant; 2002 Jan; 29(2):159-64. PubMed ID: 11850711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulary management of colony-stimulating factors.
    Whalen CR; Watson TL; Baize T; Ball A
    Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S21-7. PubMed ID: 11944611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of colony-stimulating factors: a historical perspective.
    Sylvester RK
    Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S6-12. PubMed ID: 11944613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
    Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
    J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy.
    Milkovich G; Moleski RJ; Reitan JF; Dunning DM; Gibson GA; Paivanas TA; Wyant S; Jacobs RJ
    Pharmacotherapy; 2000 Dec; 20(12):1432-40. PubMed ID: 11130215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterility of unit dose syringes of filgrastim and sargramostim.
    Singh RF; Corelli RL; Guglielmo BJ
    Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Heisrath-Evans J; Koczyk-Scripka K; Pashko S; Norgard MJ; Barnes HM; Taylor WR; Thompson KA; Smith LF; Ueno WM; Dobrzynski RF; Warren RD; Katcher D; Byrne PJ; Dunning DM; Winokur SH; Lockey JL; Cambareri RJ; Butler TP; Meister RJ; Fiegert JM
    Support Care Cancer; 1997 Jul; 5(4):289-98. PubMed ID: 9257425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine therapy after bone marrow transplantation.
    Dix SP; Gilmore CE
    Pharmacotherapy; 1996; 16(4):593-608. PubMed ID: 8840365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Harvey JH; Windsor K; Gore I; Cantrell J; Thompson KA; Taylor WR; Barnes HM; Schiff SA; Shields JA; Cambareri RJ; Butler TP; Meister RJ; Feigert JM; Norgard MJ; Moraes MA; Helvie WW; Patton GA; Mundy LJ; Henry D; Sheridan MJ
    Cancer Invest; 1998; 16(6):366-73. PubMed ID: 9679526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
    Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
    Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.